Delivery of the Theileria parva p67 antigen to cattle using recombinant vaccinia virus: IL-2 enhances protection.
To evaluate vaccinia virus as a delivery system for recombinant antigen in cattle, calves were immunized with a recombinant vaccinia virus (rVV) expressing the sporozoite surface antigen (p67) of Theileria parva (V-67) combined with those expressing bovine IL-4 (V-IL4) or IL-2 (V-IL2). The anti-p67 antibody levels detected in calves inoculated with the combination of V-67 and V-IL4 were higher than those produced by animals injected with V-67 alone or V-67 and V-IL2. On challenge with cryopreserved sporozoites, 5 of 7 animals receiving V-67 combined with V-IL2 were protected, while those receiving V-67 in conjunction with V-IL4 behaved like unimmunized control calves. Vaccination with a recombinant virus expressing a chimaeric p67(p583)/IL2 product gave rise to a lower level of protection, whereas V-IL2 provided no immunity. The results of this study demonstrate the potential of rVV as a delivery system for use in vaccination of cattle against Theileria parva infection.
International Livestock Research Institute (ILRI), Nairobi, Kenya. Y.HONDA@CGNET.COM
Y
Y
Honda
M
M
Waithaka
E L
EL
Taracha
L
L
Duchateau
A J
AJ
Musoke
D J
DJ
McKeever
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000235:genetics; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D000953:Antigens, Protozoan / Q000008:administration & dosage / Q000276:immunology; D002417:Cattle; D016503:Drug Delivery Systems; D005260:Female; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D015847:Interleukin-4 / Q000276:immunology / Q000627:therapeutic use; D008297:Male; D015800:Protozoan Proteins / Q000008:administration & dosage* / Q000276:immunology; D016052:Protozoan Vaccines / Q000008:administration & dosage* / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000276:immunology; D016797:Theileria parva / Q000276:immunology*; D013801:Theileriasis / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000276:immunology; D014616:Vaccinia virus
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D007376:Interleukin-2; D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; C114309:p67 antigen, Theileria; D015847:Interleukin-4